deltatrials

Recurrent breast carcinoma Trials in Findlay, United States

Conditions / Recurrent breast carcinoma / Findlay, United States

Recurrent breast carcinoma has been the subject of sustained clinical investigation across multiple research sites.

12 total trials for this combination

Showing top 10 of 12 trials

Trials

NCT ID Title Status Phase
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT00601900 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer COMPLETED PHASE3
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT01275677 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer COMPLETED PHASE3
NCT02595905 Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases COMPLETED PHASE2
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT02311933 Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer ACTIVE_NOT_RECRUITING
NCT02465060 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) ACTIVE_NOT_RECRUITING
NCT00785291 Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer COMPLETED PHASE3

Related Pages